Products
Community
Markets
Brokers
More

Markets
USA
Stocks
Health Technology
Biotechnology
HMTXF
Ideas

Hemostemix Inc

No trades

See on Supercharts

Overview Financials News

Ideas

Discussions Technicals Seasonals

HMTXF trade ideas

$HEM declared the addition of an entirely closely-held subsidiar Hemostemix recently declared the incorporation of PreCerv inc . (A totally closely-held subsidiary of Hemostemix). Hemostemix can grant PreCerv a world field of use licence for NCP-01 and its autologous somatic cell technology to treat central and peripheral systema nervosum diseases.

Long

by TRADECONNECT

$HEM grants worldwide field license to PreCerv Inc. Hemostemix recently granted the global field license of use of NCP-01 and its autologous stem cell therapies to PreCerv Inc. its wholly owned subsidiary to aid patients with peripheral and central nervous system conditions

Long

by TRADECONNECT

Hemostemix Inc. interest payment on convertible debenture Hemostemix Inc. announced that it will pay interest of $84,804.40 by issuing 446,339 Common Shares, using the March 2, 2022 closing price of $0.19 per share, to the convertible debenture holder in satisfaction of interest due on the outstanding principal amount of $2,500,000 for the period from inception, June 11, 2021, to December 31, 2021.

Long

by TRADECONNECT

Pending lawsuit with Accudata and aspire health science finally The perpetual lawsuit held between hemostenix and aspire health science has met its end, eventually enabling the company to gain back ultimate possession over its lost intellectual property.

Long

by InvestorRelations-1

$HEM has announced the closing of debentures Hemostemix has announced that it has closed the previously released non-brokered convertible debenture in accordance with offering $1,000 principal amount of each debenture.

Long

by InvestorRelations-1

The recovery of lost intellectual data opens door to new opportu As the court ruled in the favor of Hemostemix and all the intellectual property relating to ACP-01 was returned to Hemostemix, the management is independent to cultivate important business development strategies as well as it enables the extraction of phase 2 clinical trial data.

Long

by InvestorRelations-1

Thomas Smeenk, the CEO of Hemostemix, on the new appointment new For settling all the financial transactions of the company, Hemostemix has appointed a special advisor, Mr. Richard Groome, to the CEO, who believes that he’s a great addition to the team.

Long

by InvestorRelations-1

Hemostemix $HEM has an agreement with Aspire Health Science. Hemostemix (TSXV: $HEM) primarily deals with developing and commercializing innovative blood-derived stem cell therapies. Is now entered into an agreement with Aspire and has agreed to settle the dispute of data stealth and intellectual property infringement regarding ACP-01.

Long

by InvestorRelations-1

The closing of the settlement agreement by $HEM In connection with the previous agreement dispute, Hemostemix has recently announced the closure of the agreement and the settlement of all prosecution with Aspire Health Science in a very recent news release by the company itself.

Long

by InvestorRelations-1

$HMTXF witnesses the return of intellectual property to the comp In the very recent news release, the company announces that it possesses the entirety of its intellectual property, including all HS 12-01 Phase II clinical path information and all authentic information from Hemostemix Israel.

Long

by InvestorRelations-1

Hemostemix inc shows an Astounding Growth Hemostemix Inc. is a biotech company situated in Calgary, Canada, headed by Thomas A. Smeenk. The company manages the exploration, improvement, and assembling of inventive blood-derived stem cell therapies with marvelous recuperating and recovery properties bringing about less immunogenic variables.

by InvestorRelations-1

ACP-01 is an immortal development in the realm of medication The company’s lead candidate for phase II clinical-stage trial is doing wonders in medication, helping patients experiencing ulcers and CLI or other ischemic issues like peripheral artery disease and keeping the patients from getting their limb amputated.

Long

by InvestorRelations-1

$HMTXF -Company’s patent directory and reputation on world stage @Hemostemix has filed and owns 91 patents in more than 25 jurisdictions covering 5 different categories, and has also won world economic forum technology pioneer award with several peer reviewed articles published.

by InvestorRelations-1

Hemostemix finished the scrutiny and data audit Hemostemix $HEM has finished the detailed information review to guarantee the authenticity. The company has affirmed that the materials held by Aspire are finished and liberated from manipulation.

by InvestorRelations-1

Hemostemix Inc. $HEM Stock Updates Hemostemix Inc. (TSXV: HEM) is a biotechnology company occupied with the innovative work and the assembling and commercializing of blood-determined stem cell therapies. Shares outstanding of all classes are 67M, assessing the stocks for 52-weeks are viewed as 0.39 (high) and 0.13 (low).

Long

by InvestorRelations-1

Hemostemix advises the conclusion of the non-brokered convertibl Hemostemix refreshed another release concerning the end of a non-brokered convertible debenture. The chief sum is convertible at the choice of the debenture holder into a common share of the company at the cost of $0.175 per normal offering.

by InvestorRelations-1

HMTXF up 4% after reporting the closure of non-brokered private $HMTXF OTC:HMTXF observed a sudden spike after announcing the closure of its $2.75 Million worth of non-brokered private placement of convertible debentures unit offering

by InvestorRelations-1

Hemostemix $HEM Market Insights Hemostemix Inc. ( TSXV: $HEM ) is an innovative-driven publicly-traded biotech company. Its principal business is developing, manufacturing, and commercializing innovative blood-derived stem cell therapies. The company is currently offering a trading volume of 130K+, followed by the 30-day estimated average volume of 240.6K. TSXV:HEM

by InvestorRelations-1

$HMTXF - Stock Price is Hike on OTC Market Hemostemix is an autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. As per $HMTXF current market analysis price is 0.24445 upgraded in 3.76% and daily range 0.24445 - 0.2508

Long

by InvestorRelations-1

Hemostemix inc (TSX.V: $HEM) shows an Astounding Growth Hemostemix is a biotechnology-based company located in Calgary, Canada, headed by Thomas A. Smeenk. The company deals with researching, developing, and manufacturing innovative blood-derived stem cells with miraculous healing and regeneration properties resulting in less immunogenic factors. It is a cost-effective platform that has the power to increase the range of therapies that can cure severe diseases; being non-invasive, it doesn't trigger immune responses.

by InvestorRelations-1

Love in every #TradingView

100M+

Traders and investors use our platform.

#1

Top website in the world when it comes to all things investing.

1.5M+

Mobile reviews with 4.9 average rating. No other fintech apps are more loved.

10M+

Custom scripts and ideas shared by our users.

TradingView Chart on Instagram @fxdelta

@fxdelta

TradingView Chart on Instagram @agagata.j

@agagata.j

TradingView Chart on Instagram @mytradingsetup

@mytradingsetup

TradingView Chart on Instagram @mytradingsetup

@mytradingsetup

TradingView Chart on Instagram @youngtraderwealth

@youngtraderwealth

TradingView Chart on Instagram @ale.brovelli

@ale.brovelli

TradingView Chart on Instagram @trade_with_melker

@trade_with_melker

TradingView Chart on Instagram @neo_inversion

@neo_inversion

TradingView Chart on Instagram @miahouse9

@miahouse9

TradingView Chart on Instagram @setupstrading

@setupstrading

TradingView Chart on Instagram @bradfairbridge

@bradfairbridge

TradingView Chart on Instagram @stocktcm

@stocktcm

TradingView Chart on Instagram @tradeviewindore

@tradeviewindore

TradingView Chart on Instagram @reubenblameyfx

@reubenblameyfx

TradingView Chart on Instagram @my_trading_floor

@my_trading_floor

TradingView Chart on Instagram @tanhef

@tanhef

TradingView Chart on Instagram @setupstrading

@setupstrading

TradingView Chart on Instagram @felicitytradingcompany

@felicitytradingcompany

Whatever the trade

Here's why Here's why

Products

Supercharts
Pine Script®
Stock Screener
ETF Screener
Bond Screener
Crypto Coins Screener
CEX Screener
DEX Screener
Stock Heatmap
ETF Heatmap
Crypto Heatmap
Economic Calendar
Earnings Calendar
Sparks
News
TradingView Desktop
Mobile app
CME Group futures
Eurex futures
US stocks bundle

Company

About
Features
Pricing
Social network
Wall of Love
Athletes
Manifesto
Careers
Blog
Security vulnerability
Status page
Terms of use
Disclaimer
Privacy policy
Cookies policy
Media kit
Accessibility statement
Tarot cards for traders
TradingView merch store

Community

Refer a friend
Ideas
Scripts
House rules
Moderators
Pine Wizards
Pine freelancers
Chat

For business

Widgets
Advertising
Charting libraries
Lightweight Charts™
Advanced Charts
Trading Platform
Brokerage integration
Partner program
Education program

Select market data provided by ICE Data Services Select reference data provided by FactSet. Copyright © 2025 FactSet Research Systems Inc. © 2025 TradingView, Inc. US phone number 833 247 1523